Recombinant human thrombopoietin - Biolotus

Drug Profile

Recombinant human thrombopoietin - Biolotus

Alternative Names: rhTPO - Biolotus; TPO - Biolotus; ZYPOTIN-TPO

Latest Information Update: 18 Jun 2015

Price : $50

At a glance

  • Originator Biolotus
  • Class Colony-stimulating factors; Glycoproteins
  • Mechanism of Action Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Thrombocytopenia

Most Recent Events

  • 18 Jun 2015 Launched for Thrombocytopenia in Brazil (SC) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top